Cesca Therapeutics Reports Third Quarter Fiscal 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Cesca Therapeutics (KOOL) Misses Q3 EPS by 2c
June 23, 2015 4:07 PM EDTCesca Therapeutics (NASDAQ: KOOL) reported Q3 EPS of ($0.12), $0.02 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $4 million versus the consensus estimate of $4.58 million.
"We made strides in several key areas," said Robin C. Stracey, Chief Executive Officer of Cesca Therapeutics. "We addressed several merger-related housekeeping issues including the development of a remediation plan to eliminate an identified material weakness in our corporate... More
